Capital One starts Immutep at Buy given ‘pipeline in a product’

Capital One initiated coverage of Immutep with an Overweight rating and $10 price target. . Immutep is a pure-play LAG-3 company with assets for both autoimmune disease and cancer, including a lead drug candidate in several large oncology indications, the analyst tells investors in a research note. The firm views eftilagimod as a “pipeline in a product” with trials across five oncology indications underway.